Monday, 9 April 2018

Novartis pays big premium to get hands on AveXis in $8.7 billion deal

/ by  / in , / with No comments /

ZURICH (Reuters) - Novartis plans to buy AveXis for $218 per share in a $8.7 billion cash deal, adding a therapy hopeful for spinal muscular atrophy (SMA) to the Swiss drugmaker's pipeline that is expected to reap billions in annual sales.


from Reuters: Top News https://ift.tt/2uYtE1h
//

Related Posts:

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)